Skip to main content
Caplight Logo









Ternary Therapeutics

Ternary Therapeutics

Private
LondonHealthcare & Life Scienceshttps://www.ternarytx.co.uk/

Last Round

Seed

Mar 16, 2026

Total Funding Raised

$4.6M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Ternary Therapeutics is a biotechnology company that develops an AI-driven platform for the rational design of molecular glue therapeutics targeting immunological disorders.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, ML Platforms

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

molecular gluedrug discoveryAI drug discoverytech-biorational drug designprotein-protein interactionsundruggable targetsmolecular dynamicsvirtual screeningin silico drug designcomputational biologyprotein structure predictionbiotech platformsmall molecule therapeuticsAI-driven R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ternary Therapeutics Comparables

Compare Ternary Therapeutics with similar companies based on industry and business-model similarity.

Ternary Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
TenAces Biosciences
87%
Celeris Therapeutics
80%
Magnet Biomedicine
79%

Ternary Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMar 16, 2026
SeedFeb 27, 2025

Key People

Founding team and executive leadership

Andrew Potterton

Chief Technology Officer and Co-Founder

Founding Team

Chris Tame

Founder and CEO

Founding Team

Ternary Therapeutics Investors

Notable investors and investment history

Ternary Therapeutics investors
InvestorRounds
Pace VenturesSeed
DaphniSeed
UK Innovation & Science Seed FundSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 19, 2026

    Grew 21% QoQ, from 14 to 17 employees.

  • Jun 1, 2026

    Grew 25% QoQ from 12 to 15 employees.

Ternary Therapeutics Filings

Explore SEC and related filing metadata, where available.

Ternary Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Ternary Therapeutics's valuation, stock price, and market status.

Is TernaryTx a public or private company?

TernaryTx is a private company.

What is the current stock price of TernaryTx?

TernaryTx is a private company with no public stock price. No recent secondary market data is available.

How much is TernaryTx worth (valuation)?

Valuation information for TernaryTx is not publicly available.

Can I buy TernaryTx stock?

TernaryTx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was TernaryTx's last funding round?

TernaryTx's most recent funding round was Seed on February 27, 2025.

Who are the main investors in TernaryTx?

Key investors in TernaryTx include Pace Ventures.

Will TernaryTx IPO soon?

No public IPO plans have been announced for TernaryTx.

How can I track TernaryTx secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor TernaryTx's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLondon
Employee Range14
Year Founded2024
Last FundingMar 16, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?